TPST - What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday? | Benzinga
Shares of Tempest Therapeutics Inc (NASDAQ:TPST) are trading lower on Thursday, with a session volume of 21 million as per data from Benzinga Pro.
The company announced new data from the ongoing Phase 1b/2 clinical study on amezalpat2 (TPST-1120).
The drug candidate delivered a six-month improvement in median overall survival advantage when combined with atezolizumab and bevacizumab compared to atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), the most common type of primary liver cancer.
At the cutoff date of February 14, 2024, the new data from 40 patients randomized to the amezalpat arm and 30 patients ...